The DOI matches its Crossref record; 499 of the 502 references it cites were found in a registry or an index.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Open accessAbstract
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance document reflects many advances in the field pertinent to any practitioner caring for patients with NAFLD and emphasizes advances in noninvasive risk stratification and therapeutics. A separate guideline focused on the management of patients with NAFLD in the context of diabetes has been written jointly by the American Association of Clinical Endocrinology and AASLD.2 Given the significant growth in pediatric NAFLD, it will not be covered here to allow for a more robust discussion of the diagnosis and management of pediatric NAFLD in the upcoming AASLD Pediatric NAFLD Guidance. A “Guidance” differs from a “Guideline” in that it is not bound by the Grading of Recommendations, Assessment Development and Evaluation system. Thus, actionable statements rather than formal recommendations are provided herein. The highest available level of evidence was used to develop these statements, and, where high-level evidence was not available, expert opinion was used to develop guidance statements to inform clinical practice. Key points highlight important concepts relevant to understanding the disease and its management. The most profound advances in NAFLD relevant to clinical practice are in biomarkers and therapeutics. Biomarkers and noninvasive tests (NITs) can be used clinically to either exclude advanced diseases or identify those with a high probability of cirrhosis.3,4 NIT “cut points” vary with the populations studied, underlying disease severity, and clinical setting. Those proposed in this guidance are meant to aid decision-making in the clinic and are not meant to be interpreted in isolation. Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest. Although the definitive diagnosis and staging of NASH remain linked to histology, noninvasive tools can now be used to assess the likelihood of significant fibrosis, predict risk of disease progression and decompensation, make management decisions, and, to some degree, assess response to treatment. There is an ongoing debate over the nomenclature of fatty liver disease, which had not been finalized at the time this guidance was published. At the culmination of a rigorous consensus process, it is intended that any formal change in nomenclature will advance the field without a negative impact on disease awareness, clinical trial endpoints, or the drug development/approval process. Furthermore, it should allow for the emergence of newly recognized disease subtypes to address the impact of disease heterogeneity, including the role of alcohol, on disease progression and response to therapy. Input from patients has been central to all stages of the consensus process to ensure the minimization of nomenclature-related stigma. DEFINITIONS NAFLD is an overarching term that includes all disease grades and stages and refers to a population in which ≥5% of hepatocytes display macrovesicular steatosis in the absence of a readily identified alternative cause of steatosis (eg, medications, starvation, monogenic disorders) in individuals who drink little or no alcohol (defined as < 20 g/d for women and <30 g/d for men). The spectrum of disease includes NAFL, characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation, and NASH, which is additionally characterized by the presence of inflammation and cellular injury (ballooning), with or without fibrosis, and finally cirrhosis, which is characterized by bands of fibrous septa leading to the formation of cirrhotic nodules, in which the earlier features of NASH may no longer be fully appreciated on a liver biopsy. UPDATE ON EPIDEMIOLOGY AND NATURAL HISTORY The prevalence of NAFLD and NASH is rising worldwide in parallel with increases in the prevalence of obesity and metabolic comorbid disease (insulin resistance, dyslipidemia, central obesity, and hypertension).5,6 The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population7–9 and varies with the clinical setting, race/ethnicity, and geographic region studied but often remains undiagnosed.10–14 The associated economic burden attributable to NASH is substantial.15–17 The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.14 This study also highlights that since the publication of a prior prospective prevalence study,18 the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased >2-fold. This is supported by the projected rise in NAFLD prevalence by 2030, when patients with advanced hepatic fibrosis, defined as bridging fibrosis (F3) or compensated will the proj
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on this, it seems reasonable to conclude that should patients continue to complete guideline-based amounts of aerobic exercise over a longer duration, fibrosis improvement may follow [35, 36].”
From Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interventions in diet and physical activity are considered to be the cornerstone of management in the whole MASLD spectrum [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there is no consensus on the optimal diet for treating MASLD, the EASL-EASD-EASO guidelines recently recommended the MD as the preferred option [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current guidelines recommend weight loss through dietary modifications, increased physical activity, or both combined in MASLD patients [7, 11, 12].”
The cited source says what the claim attributes to it.
In the citing paper
“Various scienti fi c societies have recommended clinical care pathways with an emphasis on the use of non-invasive tests (NITs) and the liaison between primary care/non-hepatology and hepatology settings.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [126]
In the citing paper
“GLP-1RA-based drugs have been proven beneficial to some extent in dedicated trials and should be considered in patients with obesity and/or T2D and metabolic dysfunction-associated steatohepatitis (MASH)90.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–499 of 499
Tamaki, N., Ahlholm, N., Luukkonen, P. K., Porthan, K., Sharpton, S. R., Ajmera, V., Kono, Y., Dave, S., Ahmed, A., Sundaram, V., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162513 · Cited by 69
Sarkar, M. A., Wellons, M., Cedars, M. I., VanWagner, L. B., Gunderson, E. P., Ajmera, V. H., Torchen, L. C., Siscovick, D. S., Carr, J. J., Terry, J. G., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.44 · Cited by 68
Self-citationIncreased hepatic density and phospholipidosis due to amiodarone
Goldman, I. S., Winkler, M. L., Raper, S. E., Barker, M., Keung, E., Goldberg, H., & Td, B. (1985) · American Journal of Roentgenology · doi:10.2214/ajr.144.3.541 · Cited by 66
Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications
Adams, T. D., Arterburn, D. E., Nathan, D. M., & Eckel, R. H. (2016) · Diabetes Care · doi:10.2337/dc16-0157 · Cited by 65
Awazawa, M., Gabel, P., Tsaousidou, E., Nolte, H., Krüger, M., Schmitz, J., Ackermann, P., Brandt, C., Altmüller, J., Motameny, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4420 · Cited by 65
Elevated liver enzymes in Turner syndrome during a 5‐year follow‐up study
El‐Mansoury, M., Berntorp, K. E., Bryman, I., Hanson, C., Innala, E., Karlsson, A., & Landin‐Wilhelmsen, K. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03166.x · Cited by 63
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd, J. T., & Cusi, K. J. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 63
Zeng, D., Wang, Y., Chen, Y., Li, D., Li, G., Xiao, H., Hou, J., Wang, Z., Hu, L., Wang, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720620 · Cited by 62
Gidener, T., Dierkhising, R. A., Mara, K. C., Therneau, T. M., Venkatesh, S. K., Ehman, R. L., Yin, M., & Allen, A. M. (2023) · Hepatology · doi:10.1002/hep.32594 · Cited by 62
ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis
Mahli, A., Saugspier, M., Koch, A., Sommer, J., Dietrich, P., Lee, S. M. L., Thasler, R., Schulze‐Luehrmann, J., Lührmann, A., Thasler, W. E., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312485 · Cited by 61
Patel, S. S., Guzmán, L. A., Lin, F., Pence, T. S., Reichman, T., John, B. V., Celi, F. S., Liptrap, E., Bhati, C. S., & Siddiqui, M. S. (2018) · Liver Transplantation · doi:10.1002/lt.25067 · Cited by 61
Self-citationSleep-disordered breathing, circulating exosomes, and insulin sensitivity in adipocytes
Khalyfa, A., Gozal, D., Masa, J. F., Marín, J. M., Qiao, Z., Corral, J., González, M., Martí, S., Gozal, D., Egea, C., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0099-9 · Cited by 61
Tamaki, N., Imajo, K., Sharpton, S. R., Jung, J., Kawamura, N., Yoneda, M., Valasek, M. A., Behling, C. A., Sirlin, C. B., Nakajima, A., et al. (2021) · Hepatology · doi:10.1002/hep.32145 · Cited by 60
Self-citationHamurcu, P., Kaya, E., Alphan, E., & Yilmaz, Y. N. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001656 · Cited by 60
Corey, K. E., Vuppalanchi, R., Wilson, L., Cummings, O. W., Chalasani, N., & CRN, T. N. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13035 · Cited by 57
Wakolbinger, M., Kruschitz, R., Kienbacher, C., Traussnigg, S., Langer, F. B., Schindler, K., Würger, T., Wrba, F., Trauner, M. A., Prager, G., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2123-2 · Cited by 57
Allard, J., Bucher, S., Massart, J., Ferron, P., Guillou, D. L., Loyant, R., Daniel, Y., Launay, Y., Buron, N., Begriche, K., et al. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09537-1 · Cited by 57
Drug-Induced Steatohepatitis Leading to Cirrhosis: Long-Term Toxicity of Amiodarone Use
Raja, K., Thung, S. N., Fiel, M. I., & Chang, C. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1240011 · Cited by 56
Sargeant, J. A., Aithal, G. P., Takamura, T., Misu, H., Takayama, H., Douglas, J. A., Turner, M. C., Stensel, D. J., Nimmo, M. A., Webb, D. R., et al. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2017-0639 · Cited by 56
Canada, J. M., Abbate, A., Collen, R., Billingsley, H., Buckley, L. F., Carbone, S., Trankle, C. R., Idowu, M. O., Kadariya, D., Tassell, B. W. V., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.10.027 · Cited by 56
Self-citationMcQueen, A. E., Kanamaluru, D., Yan, K., Gray, N. E., Wu, L., Li, M.-L., Chang, A., Hasan, A., Stifler, D., Koliwad, S. K., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.803973 · Cited by 56
Canbay, A. E., Kachru, N., Haas, J. S., Sowa, J., Meise, D., & Ozbay, A. B. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16016 · Cited by 56
Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology
Corey, K. E., Misdraji, J., Gelrud, L. G., King, L. Y., Zheng, H., Malhotra, A., & Chung, R. T. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3650-8 · Cited by 54
Role of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Gardner, C. J., Irwin, A. J., Daousi, C., McFarlane, I. A., Joseph, F., Bell, J. D., Thomas, E. L., Adams, V. L., Kemp, G. J., & Cuthbertson, D. J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0002 · Cited by 52
Metabolic Parameters and Nonalcoholic Fatty Liver Disease in Hypopituitary Men
Hong, J., Kim, J. Y., Kim, Y.-E., & Lee, E. J. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1265217 · Cited by 50
Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base
Mahawar, K. K., Parmar, C. D., Graham, Y. N. H., Abouleid, A., Carr, W. R. J., Jennings, N., Schroeder, N., & Small, P. K. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1916-z · Cited by 49
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2985 · Cited by 49
Tuong, T. T. K., Khoa, T. D., Phu, P. Q. T., Hong, T. N. D., Dinh, T. C., & Chu, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030159 · Cited by 49
Sporea, I., Mare, R. G., Popescu, A., Nistorescu, S., Bâldea, V., Șirli, R., Braha, A., Sima, A. C., Timar, R. Z., & Lupușoru, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041032 · Cited by 49
Dennis, A., Mouchti, S., Kelly, M., Fallowfield, J. A., Hirschfield, G. M., Pavlides, M., & Banerjee, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-71995-8 · Cited by 49
Cideb controls sterol‐regulated ER export of SREBP/SCAP by promoting cargo loading at ER exit sites
Su, L., Zhou, L., Chen, F., Wang, H., Qian, H., Sheng, Y., Zhu, Y., Yu, H. J., Gong, X., Cai, L., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100156 · Cited by 48
Chandan, S., Mohan, B. P., Khan, S. R., Facciorusso, A., Ramai, D., Kassab, L. L., Bhogal, N., Asokkumar, R., Lopez-Nava, G., McDonough, S., et al. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05084-0 · Cited by 46
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis
Loomba, R. S., Jain, A., Diehl, A. M., Guy, C. D., Portenier, D. D., Sudan, R., Singh, S., Faulkner, C., Richards, L., Hester, K. D., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.004 · Cited by 46
Self-citationClinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus
Chen, K., Sng, W. K., Quah, J. H. M., Liu, J., Chong, B. Y., Lee, H. K., Wang, X. F., Tan, N. C., Chang, J. P.-E., Tan, H. C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236977 · Cited by 46
Yang, Y. J., Kim, K. M., An, J., Lee, D. B., Shim, J. H., Lim, Y., Lee, H. C., Lee, Y. S., Ahn, J., Jung, K. H., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.04.017 · Cited by 45
Soresi, M., Cabibi, D., Giglio, R. V., Martorana, S., Guercio, G., Porcasi, R., Terranova, A., Lazzaro, L. A., Emma, M. R., Augello, G., et al. (2020) · BioMed Research International · doi:10.1155/2020/5023157 · Cited by 45
Alqahtani, S. A., Golabi, P., Paik, J. M., Lam, B. P., Moazzez, A. H., Elariny, H. A., Goodman, Z. D., & Younossi, Z. M. (2021) · Obesity Surgery · doi:10.1007/s11695-020-04996-1 · Cited by 45
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
Camporez, J. P., Asrih, M., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., & Jornayvaz, F. R. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0136 · Cited by 44
Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis.
Xu, R., Tao, A., Zhang, S., Deng, Y., & Chen, G. (2015) · Europe PMC (PubMed Central) · Cited by 44
Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease
Salvoza, N. C., Giraudi, P. J., Tiribelli, C., & Rosso, N. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00005 · Cited by 44
Tamaki, N., Higuchi, M., Kurosaki, M., Loomba, R. S., Izumi, N., Inada, K., Kirino, S., Yamashita, K., Sekiguchi, S., Hayakawa, Y., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.021 · Cited by 44
Self-citationYao, Y., Miao, X., Zhu, D., Li, D., Zhang, Y., Song, C., & Liu, K. (2019) · Endocrine · doi:10.1007/s12020-019-01982-1 · Cited by 43
Woreta, T. A., Natta, M. L. V., Lazo, M., Krishnan, A., Neuschwander‐Tetri, B. A., Loomba, R. S., Diehl, A. M., Abdelmalek, M. F., Chalasani, N., Gawrieh, S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266859 · Cited by 43
Self-citationHeinitz, S., Hollstein, T., Ando, T., Walter, M. F., Basolo, A., Krakoff, J. A., Votruba, S. B., & Piaggi, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154303 · Cited by 42
Beysen, C., Ruddy, M. K., Stoch, A., Mixson, L. A., Rosko, K., Riiff, T. J., Turner, S., Hellerstein, M. K., & Murphy, E. J. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00470.2017 · Cited by 41
Fujiwara, Y., Eguchi, S., Murayama, H., Takahashi, Y., Toda, M., Imai, K., & Tsuda, K. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.68 · Cited by 41
Hirose, S., Matsumoto, K., Tatemichi, M., Tsuruya, K., Anzai, K., Arase, Y., Shiraishi, K., Suzuki, M., Ieda, S., & Kagawa, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241770 · Cited by 40
Simón, J., Goikoetxea-Usandizaga, N., Serrano-Maciá, M., Fernández-Ramos, D., de Urturi, D. S., Gruskos, J. J., Fernández-Tussy, P., Lachiondo-Ortega, S., González-Recio, I., Rodríguez-Agudo, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.043 · Cited by 40
The Canals of Hering Might Represent a Target of Methotrexate Hepatic Toxicity
Hytiroglou, P., Tobias, H., Saxena, R., Abramidou, M., Papadimitriou, C. S., & Theise, N. D. (2004) · American Journal of Clinical Pathology · doi:10.1309/5hr9-0tnc-4q4j-rxwx · Cited by 38
Tsunoda, K., Kitano, N., Kai, Y., Jindo, T., Uchida, K., & Arao, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16631 · Cited by 38
van Kleef, L. A., Hofman, A., Voortman, T., & de Knegt, R. J. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001584 · Cited by 38
Miele, L., Michele, T. D., Marrone, G., Isgrò, M., Basile, U., Cefalo, C., Biolato, M., Vecchio, F., Rapaccini, G., Gasbarrini, A., et al. (2017) · International Journal of Biological Markers · doi:10.5301/ijbm.5000292 · Cited by 37
MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
Loomba, R. (2021) · Hepatology · doi:10.1002/hep.31624 · Cited by 36
Self-citationKang, K. A., Jun, D. W., Kim, M. S., Kwon, H., & Nguyen, M. H. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15626 · Cited by 35
Patel, N. S., Hooker, J. C., Gonzalez, M. P., Bhatt, A., Nguyen, P., Ramirez, K., Richards, L., Rizo, E., Hernandez, C., Kisseleva, T., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.09.150 · Cited by 34
Self-citationRoccarina, D., Best, L. M., Freeman, S. C., Roberts, D. A., Cooper, N. J., Sutton, A. J., Benmassaoud, A., Torres, M. C. P., Prat, L. I., Csenar, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013121.pub2 · Cited by 34
Bril, F., Kadiyala, S., Portillo-Sánchez, P., Sunny, N. E., Biernacki, D., Maximos, M., Kalavalapalli, S., Lomonaco, R., Suman, A., & Cusi, K. J. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2015-000019 · Cited by 33
Xu, H., Chen, L., Zou, J., Yi, H., Guan, J., Gu, M., Feng, Y., & Yin, S. (2020) · Respiratory Research · doi:10.1186/s12931-020-01416-x · Cited by 33
The Canals of Hering Might Represent a Target of Methotrexate Hepatic Toxicity
Hytiroglou, P., Tobias, H., Saxena, R., et al. (2004) · American Journal of Clinical Pathology · doi:10.1309/5hr90tnc4q4jrxwx · Cited by 32
Udelsman, B. V., Corey, K. E., Lindvall, C. J., Gee, D. W., Meireles, O. R., Hutter, M. M., Chang, D. C., & Witkowski, E. R. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.01.035 · Cited by 30
Torres, M. C. P., Best, L. M., Freeman, S. C., Roberts, D. A., Cooper, N. J., Sutton, A. J., Roccarina, D., Benmassaoud, A., Prat, L. I., Williams, N. R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013122.pub2 · Cited by 30
Postrach, E., Aspalter, R. M., Elbelt, U., Koller, M. T., Longin, R., Schulzke, J., & Valentini, L. (2013) · Journal of Medical Internet Research · doi:10.2196/jmir.2648 · Cited by 29
Nonalcoholic steatohepatitis in nonobese patients
Cusi, K. J. (2016) · Hepatology · doi:10.1002/hep.28839 · Cited by 29
Lavín-Alconero, L., Fernández-Lanas, T., Iruzubieta, P., Arias, M., Rodríguez-Duque, J. C., Rivas, C., Cagigal, M. L., Montalbán, C., Useros, A. L., Álvarez-Cancelo, A., et al. (2021) · Trials · doi:10.1186/s13063-021-05695-7 · Cited by 29
Concentration‐dependent response to pioglitazone in nonalcoholic steatohepatitis
Kawaguchi‐Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K. J., & Frye, R. F. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14111 · Cited by 28
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 27
Meng, G., Zhang, B., Yu, F., Li, C., Zhang, Q., Liu, L., Wu, H., Xia, Y., Bao, X., Shi, H., et al. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1485-0 · Cited by 26
Corey, K. E., Wilson, L., Altınbaş, A., Yates, K. P., Kleiner, D. E., Chung, R. T., Krauss, R. M., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15216 · Cited by 26
Self-citationAbdallah, M., Brown, L., Provenza, J., Tariq, R., Gowda, S. N., & Singal, A. K. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100738 · Cited by 26
The association of nonalcoholic steatohepatitis and obstructive sleep apnea
Asfari, M. M., Niyazi, F., Lopez, R., Dasarathy, S., & McCullough, A. J. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000973 · Cited by 25
Le, P., Chaitoff, A. M., Rothberg, M. B., McCullough, A. J., Gupta, N. M., & Alkhouri, N. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.023 · Cited by 25
Yamamoto, N. S., Oliveira, M. B. M., Campello, A. P., Lopes, L. C. V., & Kluppel, M. L. W. (1988) · Cell Biochemistry and Function · doi:10.1002/cbf.290060110 · Cited by 24
Birzniece, V., Barrett, P. H. R., & Ho, K. K. Y. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0151 · Cited by 24
Mirhashemi, S. H., Hakakzadeh, A., Yeganeh, F. E., Oshidari, B., & Rezaee, S. P. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100190 · Cited by 24
Siddiqui, M. S., Carbone, S., Vincent, R. J., Patel, S. S., Driscoll, C. J., Celi, F. S., Billingsley, H., Rotelli, B., John, B. V., Potere, N., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.008 · Cited by 22
Self-citationVadera, S., Yong, C. W. K., Gluud, L. L., & Morgan, M. Y. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012673.pub2 · Cited by 22
Patel, S. S., Siddiqui, M. B., Roman, J. H., Zhang, E. D., Lee, E., Shen, S., Faridnia, M., Mintini, R. J., Boyett, S. L., Idowu, M. O., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.039 · Cited by 22
Self-citationFu, Y., Zhang, N., Tang, W., Bi, Y., Zhu, D., Chu, X., Shan, X., Shen, Y., Sun, X., & Feng, W. (2022) · Hepatology International · doi:10.1007/s12072-022-10347-2 · Cited by 21
Mazzini, G. S., Augustin, T., Noria, S. F., Romero‐Marrero, C., Li, N., Hameed, B., Eisenberg, D., Azagury, D. E., & Ikramuddin, S. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.015 · Cited by 20
Back to Byzance: Querelles byzantines over NASH and fibrosis
Ratziu, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.024 · Cited by 19
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents
Hazlehurst, J., Lim, T. R., Charlton, C. A., Miller, J. J. J. J., Gathercole, L., Cornfield, T., Nikolaou, N., Harris, S., Moolla, A., Othonos, N., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100177 · Cited by 19
(2000) · Time to knit · doi:10.1016/j.yonc.2013.05.031 · Cited by 18
A robust gene expression signature for NASH in liver expression data
Hasin-Brumshtein, Y., Sakaram, S., Khatri, P., He, Y. D., & Sweeney, T. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-06512-0 · Cited by 18
Dayton, K. A., Bril, F., Barb, D., Lai, J., Kalavalapalli, S., & Cusi, K. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251449 · Cited by 17
Self-citationRisk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer
Kouzu, K., Tsujimoto, H., Nishikawa, M., Harada, M., Sugihara, T., Nagata, H., Hiraki, S., Yaguchi, Y., Takahata, R., Nomura, S., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-01009-8 · Cited by 16
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
Ochiai, Y., Kawamura, Y., Kobayashi, M., Shindoh, J., Kobayashi, Y., Okubo, S., Muraishi, N., Kajiwara, A., Iritani, S., Fujiyama, S., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13572 · Cited by 16
Brandman, D., Boyle, M., McPherson, S., Natta, M. L. V., Sanyal, A. J., Kowdley, K. V., Neuschwander‐Tetri, B. A., Chalasani, N., Abdelmalek, M. F., Terrault, N. A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16874 · Cited by 16
Self-citationProgression to Cirrhosis Leads to Improvement in Atherogenic Milieu
Patel, S. S., Siddiqui, M. B., Chandrakumaran, A., Rodríguez, V., Faridnia, M., Roman, J. H., Zhang, E. D., Patrone, M. V., Kakiyama, G., Walker, C. H., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06196-4 · Cited by 15
Self-citationYang, A., Nguyen, M., Ju, I. E., Brancatisano, A., Ryan, B., & van der Poorten, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-93294-6 · Cited by 15
Ciardullo, S., Pizzi, M., Pizzi, P., Oltolini, A., Muraca, E., & Perseghin, G. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05885-x · Cited by 15
Udelsman, B. V., Corey, K. E., Hutter, M. M., Chang, D. C., & Witkowski, E. R. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.09.037 · Cited by 14
Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH
Buryska, S. M., Ahn, J. C., Allen, A. M., Simha, V., & Simonetto, D. A. (2021) · Hepatology · doi:10.1002/hep.31988 · Cited by 14
[750] A PILOT TRIAL OF FENOFIBRATE FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE
Pérez-Carreras, M., Fernández‐Miranda, C., Colina, F., López-Alonso, G., Vargas, C., & Solis-Herruzo, T. A. (2007) · Journal of Hepatology · doi:10.1016/s0168-8278(07)62348-4 · Cited by 12
Landete, P., Fernández-García, C. E., Orzaiz, B. A., Olivo, M. H., Acosta-Gutiérrez, C. M., Zamora-García, E., Ancochea, J., González‐Rodríguez, Á., & García‐Monzón, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.808417 · Cited by 11
George, E., Reddy, A., Nicoll, A., Ryan, M., Itsiopoulos, C., Abbott, G., Johnson, N., Sood, S., Roberts, S., & Tierney, A. (2022) · Figshare · doi:10.26181/23550027 · Cited by 7
935 VISCERAL FAT AS A STRONG AND INDEPENDENT RISK FACTOR OF NONALCOHOLIC FATTY LIVER DISEASE
Kim, D., Park, B., Kim, W., Jung, Y.-S., Kim, Y. J., Yoon, J.-H., Kim, J. L., & Lee, H. S. (2008) · Journal of Hepatology · doi:10.1016/s0168-8278(08)60937-x · Cited by 4
The Importance of Glycemic Equipoise in NASH
Allen, A. M., & Neuschwander‐Tetri, B. A. (2021) · Hepatology · doi:10.1002/hep.31866 · Cited by 3
Self-citationA Robust Gene Expression Signature for NASH in Liver Expression DataPreprint
Hasin-Brumshtein, Y., Sakaram, S., Khatri, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-944703/v1 · Cited by 2
Cited by
Sorted by citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
“Moreover, this nomenclature process, in line with published guidance [21,28,29], is not advocating for the routine use of tests to con fi rm hepatic steatosis although, in reality, most, if not all, patients will usually have imaging at some point.”
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citation
Metadata
- Authors
- Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R.
- Affiliations
- University of Chicago (US)
- Saint Louis University School of Medicine, Saint Louis, Missouri, USA
- Virginia Commonwealth University (US)
- Mayo Clinic (US)
- University of Virginia (US)
- University of Florida Health (US)
- National Institutes of Health (US)
- University of California San Diego (US)
- Corresponding author
- Rinella, Mary E.
- ORCID
- Venue
- Hepatology
- Published
- 2023-03-17
- Volume
- 77
- Issue
- 5
- Pages
- 1797-1835
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10735173
- OpenAlex
- W4318923555
- Cited by
- 2,667
- References
- 502
- Citations by year
- 2026: 849 · 2025: 845 · 2024: 691 · 2023: 281
- FWCI
- 532.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- American Association for the Study of Liver Diseases
- NGM Biopharmaceuticals
- Novo Nordisk
- National Institutes of Health
- Allergan
- National Cancer Institute (ZICBC010685)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, non-invasive risk stratification, non-invasive tests, fibrosis staging, liver cirrhosis
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
